RxDoctor Payments Data

Denise Goodman, NP

Nurse Practitioner · Union City, NJNPI 1730449505

Payments from drug & device makers

$3,471in general payments, 2019–2025

Across 177 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$582
  • AstraZeneca$529
  • Akebia Therapeutics Inc$367
  • Vifor Pharma, Inc.$347
  • Otsuka America Pharmaceutical, Inc.$335
  • Ardelyx, Inc.$303
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$3,41998%
  • Education$532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,471 in reported general payments places this provider in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$27,009
Medicare patients
79
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex62$67,039
RayaldeeCalcifediol43$64,358
AuryxiaFerric Citrate28$59,527
VelphoroSucroferric Oxyhydroxide29$55,410
XphozahTenapanor Hcl11$32,913
LokelmaSodium Zirconium Cyclosilicate31$31,823
FarxigaDapagliflozin Propanediol48$30,300
Sevelamer Carbonate198$17,801
RenvelaSevelamer Carbonate25$17,264
ProcritEpoetin Alfa11$11,572
Cinacalcet Hcl28$9,113
Paricalcitol84$6,128
VascepaIcosapent Ethyl14$4,662
Icosapent Ethyl12$2,428
Allopurinol217$1,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$228$64,35843 claims
AstraZenecaLokelma, Farxiga$529$62,12379 claims
Akebia Therapeutics IncAuryxia$367$59,52728 claims
Fresenius USA Marketing, Inc.Velphoro$267$55,41029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Union City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →